BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Active Biotech AB (BTPC) Interim Report January - March 2013


4/25/2013 9:09:42 AM

LUND, SWEDEN--(Marketwired - April 25, 2013) -


Laquinimod

· first patient enrolled in CONCERTO, the third Phase III placebo-controlled study for the treatment of relapsing-remitting multiple sclerosis

· data presented at AAN showed reduced disability progression for multiple sclerosis patients who commenced early treatment with laquinimod compared with delayed treatment

Tasquinimod

· the Phase III study is proceeding according to plan

ANYARA

· Phase II/III study in renal cell cancer concluded

· Results presented:

- study did not achieve primary clinical endpoint

- doubling of progression-free survival and overall survival in 25 percent of patients

- planning of the continued clinical development ongoing

57-57 (paquinimod)

· clinical trial in systemic sclerosis concluded, evaluation underway

ISI

· focus on submission of patents

Other information

· Active Biotech raised SEK 270 M through a directed share issue to Investor

                                      Jan - Mar       Jan - Dec

  (SEK M)                           2013    2012      2012
---------------------------------------------------------------
   *      Net sales                  2.4      2.6      227.9

   *      Operating loss             -77.0    -100.7   -163.2

   *      Net loss                   -78.0    -99.0    -175.0

   *      Earnings per share (SEK)   -1.10    -1.44    -2.54


This report is also available at www.activebiotech.com

Active Biotech AB : Interim Report January - March 2013: http://hugin.info/1002/R/1695994/558366.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1695994]


For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95

Hans Kolam
CFO
Tel: +46 (0)46-19 20 44

Active Biotech AB Corp. Reg. No. 556223-9227)
Box 724, SE-220 07
Lund
Tel: 046 (0)46-19 20 00
Fax: +46 (0)46-19 11 00



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES